IL15 and plasma cell myeloma: In a small clinical trial (of 8 patients) testing the safety, persistence, and activity of expanded NK cells in patients with high-risk relapsing myeloma, NK cells expanded from PBMCs with K562 cells expressing IL-15 and 4-1BBL were shipped overnight cryopreserved from the production site to the trial site (25).